Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.40 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18765742 | 1.00 | PRSS1 (0.44) | PRSS1PRSS2PRSS3ENPP2TAAR1 | |
| SCHEMBL25112424 | 0.85 | CYP4F2 (0.44) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL9784597 | 0.85 | CYP4F2 (0.44) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL11888529 | 0.83 | ENPP2 (0.45) | PRSS1PRSS2PRSS3ENPP2TSHR | |
| SCHEMBL3279344 | 0.83 | HDAC4 (0.47) | PRSS1PRSS2PRSS3ENPP2TSHR | |
| SCHEMBL207149 | 0.83 | ACHE (0.39) | TAAR1SLC6A2ADRB1MIFHTR2A | |
| SCHEMBL28856242 | 0.82 | PNMT (0.47) | ENPP2TAAR1SLC6A2MAOASLC6A4 | |
| SCHEMBL29342899 | 0.82 | TAAR1 (0.43) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL7887272 | 0.82 | TAAR1 (0.43) | TAAR1SLC6A2MAOASLC6A4SLC6A3 | |
| SCHEMBL26008372 | 0.82 | TAAR1 (0.43) | TAAR1SLC6A2MAOASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| CN-108617166-B | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-05-17 | — | — | CN | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| CN-108617166-A | Protein Kinase Inhibitor Benzolactam Compounds | 大冢制药株式会社 | 2018-10-02 | — | — | CN | disclosed |
| EP-3365334-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068412-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-27 | — | — | WO | disclosed |
| US-8088941-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2012-01-03 | — | — | US | disclosed |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-12-18 | — | — | US | disclosed |
| US-7378432-B2 | Glycogen synthase kinase-3 inhibitors | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2008-05-27 | — | — | US | disclosed |
| EP-1824468-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Tel Aviv University Future Technology Development L.P. (IL) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006054298-A2 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) | 2006-05-26 | — | — | WO | disclosed |
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | PRSS1 3690/4885PRSS2 4397/4885PRSS3 4574/4885 |
| US-20060069066-A1 | 3-(4-(3-guanidinophenyl)-1,2,3-triazol-1-yl)benzyl phosphoric acid hydrochloride; obesity, non-insulin dependent diabetes mellitus, insulin-dependent condition, affective disorder, neurodegenerative diseases, psychotic disease; compounds having hydrophobic moiety to a terminus of a peptide GSK-3 | GSK3A, GSK3B, PYGB | PRSS1 2631/4885PRSS2 3695/4885PRSS3 1277/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PRSS1 3690/4885PRSS2 4397/4885PRSS3 4574/4885 |
| US-20080312188-A1 | Glycogen synthase kinase-3 inhibitors | GSK3B, GSK3A, GSKIP | PRSS1 1599/4885PRSS2 3207/4885PRSS3 1413/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PRSS1 3696/4885PRSS2 4398/4885PRSS3 4586/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | PRSS1 3690/4885PRSS2 4397/4885PRSS3 4574/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | PRSS1 3755/4885PRSS2 4424/4885PRSS3 4585/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | PRSS1 3690/4885PRSS2 4397/4885PRSS3 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.